A study published in Lancet Microbe suggests that higher rates of colorectal, bladder, and prostate cancers in industrialised countries may be linked to two strains of E.coli that produce a substance known as colibactin. Researchers propose that targeting these strains with treatments or vaccines could reduce cancer risk. The study also highlights the potential for developing therapeutic probiotics to displace harmful bacterial strains. Further investigation is needed to clarify the role of colibactin in cancer, but the findings indicate a possible connection between E.coli strains and cancer rates, suggesting that interventions could have significant public health benefits.
Source link
Possible vaccine target against bowel, bladder and prostate cancers identified in new research
